Country for PR: United States
Contributor: PR Newswire New York
Tuesday, February 07 2023 - 10:00
Suvoda Introduces Extensible Software Platform Bringing Proven Tech Innovation to Clinical Trial Management
PHILADELPHIA, Feb. 7, 2023 /PRNewswire-AsiaNet/ --

  -- Platform reduces friction across the eConsent, IRT, and eCOA user 
     experience for sponsors, CROs, sites and patients.

Suvoda LLC ( 
) , a global clinical trial technology company that specializes in complex 
studies in therapeutic areas like oncology, central nervous system (CNS), and 
rare disease, today unveiled a purpose-built software platform designed 
specifically to provide drug trial sponsors and sites a seamless way to manage 
complex, mission-critical, and time-sensitive moments on the patient journey. 
Click to tweet ( 
) .

Logo -

Drawing on more than a decade of expertise following the launch of its 
innovative IRT solution, and having supported more than 1,000 trials across 80 
countries, Suvoda introduces a low-code/no-code platform to the eClinical 
market unifying its eConsent, IRT, and eCOA solutions. Designed to address real 
challenges facing clinical trials, the Suvoda Platform minimizes friction 
across the user experience, while reducing and simplifying integrations, and 
strengthening data governance, so studies can be implemented more efficiently 
and with less risk of downtime.

"Clinical trials are increasingly complex, expensive, and fraught with 
challenges that are affecting trial execution – mid-study changes, data silos, 
trial delays, and more," said Jagath Wanninayake, CEO of Suvoda. "To meet these 
challenges, our team organically built a platform upon which we are delivering 
the next generation of clinical trial applications designed to handle 
complexity with ease, and reduce overall risk throughout trials. Our goal is 
always for sponsors and site users to spend less time with technology and more 
time on what is most important to them…uncovering scientific breakthroughs and 
focusing on the patients we all ultimately serve."

The Suvoda Platform enables Suvoda's IRT, eConsent, and eCOA solutions to work 
seamlessly together and harmoniously with other applications, to be easily 
tailored to meet the needs of each protocol, and to be upgradable to benefit 
from continuous enhancements. The Suvoda Platform provides a number of 
benefits, including:

Enhanced user experience and reduced workload. The new platform enables single 
sign-on and provides a consistent interface across Suvoda's eConsent, IRT, and 
eCOA solutions, with smooth user workflows that allow clinicians to move 
seamlessly from one task to the next. This reduces workload and training so 
sites can focus more of their time on research and patients. 

Rapid design and deployment of complex trials. The platform's low-code/no-code 
technology streamlines study start-up and mid-study changes, even for the most 
complex trials, while advanced design tools make customizations more practical 
and sponsor standards easier to implement. A harmonized deployment process 
across three solutions saves study teams time and effort.

Improved data workflow and reduced integrations. Suvoda's unified platform 
enables all patient and site data across eConsent, IRT, and eCOA to be 
centrally collected, managed, analyzed, and stored. This is expected to result 
in better data governance for sponsors, provide sites access to real-time 
information, and deliver a more robust eClinical ecosystem. In addition, 
customers benefit from three already-integrated solutions–eConsent, IRT and 
eCOA–while the platform's comprehensive API surface simplifies other necessary 
integrations with third-party solutions and sponsor systems.

Future-proofed eClinical programs. Users of the platform will always have the 
latest trial technology with Suvoda because upgrades can be made throughout the 
life of the trial without losing customizations. In addition, with release 
opt-in, customers can choose which updates to accept, giving them control of 
their internal validation, acceptance, and training processes. Finally, Suvoda 
makes implementing enterprise standards future-proof by allowing sponsors to 
upgrade while maintaining their proprietary processes and standards across all 
products built on the Suvoda Platform.

"Whether it's sponsors, CROs, site teams, or patients, users expect a seamless 
trial experience digitally and in-person, so we've designed the new platform to 
deliver that," said Andrew McVeigh, chief architect at Suvoda. "Suvoda offers a 
powerful trial management platform that feels like a consumer app because we've 
put the user at the center of our design. Our robust back-end and intuitive 
design puts greater control into our customers' hands and delivers the power to 
manage trials of any level of complexity."

Click here ( 
) for more information on the Suvoda Platform.

About Suvoda

Suvoda is a global clinical trial technology company specializing in complex, 
life-sustaining studies in therapeutic areas like oncology, central nervous 
system (CNS), and rare disease. Founded in 2013 by experts in eClinical 
technologies, Suvoda empowers clinical trial professionals to manage the most 
urgent moments in the most urgent trials through advanced software solutions 
delivered on a single platform. Headquartered outside Philadelphia, Suvoda also 
maintains offices in Portland, OR, Barcelona, Spain, Bucharest, Romania, and 
Tokyo, Japan. The company consistently boasts a Net Promoter Score (NPS) of 
close to 70, far exceeding the technology industry average of 50, and has been 
selected by trial sponsors and CROs to support more than 1,000 trials across 80 
countries. To learn more, visit Follow Suvoda on Twitter ( 
)  and LinkedIn ( 
) . 

For information contact:

Mara Conklin, (847) 340-6823

Kathy Zoeller, (312) 485-2422

Source - Suvoda LLC